(AFL) Aflac - Overview
Sector: Financial Services | Industry: Insurance - Life | Exchange: NYSE (USA) | Market Cap: 59.989m USD | Total Return: 10.6% in 12m
Avg Turnover: 253M
EPS Trend: 97.3%
Qual. Beats: 0
Rev. Trend: -59.9%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Aflac Incorporated (AFL) is a supplemental insurance provider operating primarily in Japan and the United States. The company specializes in voluntary insurance products, such as cancer, disability, and hospital indemnity coverage, which pay cash benefits directly to policyholders to cover expenses not met by primary health insurance. Founded in 1955, the firm utilizes a diversified distribution network including independent agents, brokers, and banking partnerships.
The business model relies heavily on the Japanese market, which historically contributes a significant portion of total revenue due to high consumer demand for cancer and medical insurance. Unlike primary insurers, supplemental providers focus on low-severity, high-frequency claims, often resulting in more predictable loss ratios. For a deeper look at these operational metrics, ValueRay offers comprehensive historical data.
Aflac distributes its products through both individual and group payroll deduction models. Its U.S. segment focuses on workplace benefits and cafeteria plans, while the Japan segment offers specialized products like child endowment and nursing care insurance to address the demographic needs of an aging population.
- Japanese Yen exchange rate fluctuations impact consolidated earnings and investment income
- Performance of Japanese cancer and medical insurance products drives total revenue
- U.S. supplemental health product expansion supports diversified premium growth
- Interest rate volatility affects fixed-income portfolio yields and capital margins
- Demographic shifts in Japan influence long-term policy demand and claims ratios
| Net Income: 4.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.40 > 1.0 |
| NWC/Revenue: 33.61% < 20% (prev 422.8%; Δ -389.2% < -1%) |
| CFO/TA 0.02 > 3% & CFO 2.93b > Net Income 4.64b |
| Net Debt (2.68b) to EBITDA (6.52b): 0.41 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (514.8m) vs 12m ago -5.87% < -2% |
| Gross Margin: 47.76% > 18% (prev 0.34%; Δ 4.74k% > 0.5%) |
| Asset Turnover: 15.15% > 50% (prev 14.26%; Δ 0.90% > 0%) |
| Interest Coverage Ratio: 24.53 > 6 (EBITDA TTM 6.52b / Interest Expense TTM 230.0m) |
| A: 0.05 (Total Current Assets 6.12b - Total Current Liabilities 0.0) / Total Assets 120b |
| B: 0.43 (Retained Earnings 52.3b / Total Assets 120b) |
| C: 0.05 (EBIT TTM 5.64b / Avg Total Assets 120b) |
| D: 0.48 (Book Value of Equity 46.7b / Total Liabilities 97.8b) |
| Altman-Z'' = 2.57 = A |
| DSRI: 0.94 (Receivables 894.0m/894.0m, Revenue 18.2b/17.1b) |
| GMI: 0.71 (GM 47.76% / 34.01%) |
| AQI: 2.44 (AQ_t 0.95 / AQ_t-1 0.39) |
| SGI: 1.06 (Revenue 18.2b / 17.1b) |
| TATA: 0.01 (NI 4.64b - CFO 2.93b) / TA 120b) |
| Beneish M = -2.42 (Cap -4..+1) = BBB |
As of June 01, 2026, the stock is trading at USD 112.42 with a total of 6,479,814 shares traded.
Over the past week, the price has changed by -4.58%,
over one month by -0.59%,
over three months by -0.31% and
over the past year by +10.61%.
Aflac has received a consensus analysts rating of 2.93. Therefore, it is recommended to hold AFL.
- StrongBuy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 111.7 | -0.6% |
P/E Trailing = 13.4697
P/E Forward = 14.5349
P/S = 3.3121
P/B = 2.0014
P/EG = 1.1813
Revenue TTM = 18.2b USD
EBIT TTM = 5.64b USD
EBITDA TTM = 6.52b USD
Long Term Debt = 7.82b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 7.91b USD (corrected: LT Debt 7.82b + ST Debt none) + Leases 86.0m
Net Debt = 2.68b USD (calculated: Debt 7.91b - CCE 5.23b)
Enterprise Value = 62.7b USD (60.0b + Debt 7.91b - CCE 5.23b)
Interest Coverage Ratio = 24.53 (Ebit TTM 5.64b / Interest Expense TTM 230.0m)
EV/FCF = 21.36x (Enterprise Value 62.7b / FCF TTM 2.93b)
FCF Yield = 4.68% (FCF TTM 2.93b / Enterprise Value 62.7b)
FCF Margin = 16.10% (FCF TTM 2.93b / Revenue TTM 18.2b)
Net Margin = 25.44% (Net Income TTM 4.64b / Revenue TTM 18.2b)
Gross Margin = 47.76% ((Revenue TTM 18.2b - Cost of Revenue TTM 9.52b) / Revenue TTM)
Gross Margin QoQ = 57.54% (prev 59.91%)
Tobins Q-Ratio = 0.52 (Enterprise Value 62.7b / Total Assets 120b)
Interest Expense / Debt = 2.91% (Interest Expense 230.0m / Debt 7.91b)
Taxrate = 16.82% (206.0m / 1.23b)
NOPAT = 4.69b (EBIT 5.64b * (1 - 16.82%))
Current Ratio = unknown (Total Current Assets 6.12b / Total Current Liabilities 0.0)
Debt / Equity = 0.35 (Debt 7.91b / totalStockholderEquity, last quarter 22.4b)
Debt / EBITDA = 0.41 (Net Debt 2.68b / EBITDA 6.52b)
Debt / FCF = 0.91 (Net Debt 2.68b / FCF TTM 2.93b)
Total Stockholder Equity = 27.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.86% (Net Income 4.64b / Total Assets 120b)
RoE = 17.20% (Net Income TTM 4.64b / Total Stockholder Equity 27.0b)
RoCE = 16.23% (EBIT 5.64b / Capital Employed (Equity 27.0b + L.T.Debt 7.82b))
RoIC = 4.91% (EBIT 5.64b / (Assets 120b - Curr.Liab 0.0 - Cash 5.23b))
WACC = 5.78% (E(60.0b)/V(67.9b) * Re(6.22%) + D(7.91b)/V(67.9b) * Rd(2.91%) * (1-Tc(0.17)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.39 | Cagr: -5.52%
[DCF] Terminal Value 77.97% ; FCFF base≈2.74b ; Y1≈3.14b ; Y5≈4.62b
[DCF] Fair Price = 131.4 (EV 69.5b - Net Debt 2.68b = Equity 66.9b / Shares 509.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.26 | EPS CAGR: 13.89% | SUE: -0.11 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -3.81% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.77 | Chg30d=-3.09% | Revisions=-67% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.79 | Chg30d=-2.53% | Revisions=-64% | Analysts=11
EPS current Year (2026-12-31): EPS=7.06 | Chg30d=-2.55% | Revisions=-60% | GrowthEPS=-5.8% | GrowthRev=-3.2%
EPS next Year (2027-12-31): EPS=7.62 | Chg30d=-1.27% | Revisions=-57% | GrowthEPS=+7.9% | GrowthRev=+1.9%
[Analyst] Revisions Ratio: -67%